Compare ProShares Ultra QQQ ETF (QLD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Sana Biotechnology Inc — how do they compare? ProShares Ultra QQQ ETF trades at $90.13, while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| QLD | SANA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $100.53 | $5.92 |
52-Week Low | $57.16 | $2.68 |
Market Cap | — | $1.03B |
Enterprise Value | — | $946.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $90.53, down 0.17% with a bullish technical signal from moving averages. The ETF has delivered over 10,000% total return since inception, demonstrating powerful compounding. Recent institutional buying includes 180 Wealth Advisors increasing their position by 29.4% in Q2 2026. Technical indicators show strong moving average support but neutral oscillators, with key support at $88-90 and resistance at $91-93 levels.
As a daily leveraged ETF tracking the Nasdaq-100, QLD offers amplified exposure to large-cap tech but carries inherent volatility risks. The current neutral RSI and ADX suggest consolidation near support levels. Institutional accumulation and strong historical performance support long-term growth potential, though leveraged structure requires careful risk management during market turbulence.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
